THE ROLE OF ACTIVIN A AND FOLLISTATIN IN THE DIFFERENTIATION BETWEEN VIABLE INTRAUTERINE PREGNANCY FROM MISSED MISCARRIAGE AND ECTOPIC PREGNANCY
Objective: The objective of the study was to investigate the role of activin A and follistatin (FS) in the differentiation between viable intrauterine pregnancy from missed miscarriage and ectopic pregnancy (EP).
Study Design: This was a case–control study.
Setting: This study was conducted at the Department of Obstetrics and Gynecology at Al-Yarmouk Teaching Hospital, from February 2017 to October 2017.
Patients and Methods: The study included 90 pregnant women, aged from 21 to 40 years old in their the first trimester attending the outpatient and inpatient clinic with single fetal pregnancy with a gestational age range between 6th and 8th weeks, they were divided into three groups; Group A: Includes 30 cases with uncomplicated pregnancies in their first trimester, Group B: Includes 30 cases diagnosed as missed miscarriages, and Group C: Includes 30 cases diagnosed as EPs.
Results: There was no significant difference in the maternal age and body mass index between the three groups, β-human chorionic gonadotropin, activin A, FS, and their ratio were significantly higher in the healthy intrauterine pregnancy compared to missed miscarriage and EP. Activin A and activin A/FS ratio had an excellent ability to discriminate EP from healthy intrauterine pregnancy, while FS alone had good ability to discriminate between EP and intrauterine pregnancy. Activin A had fair ability to discriminate missed miscarriage from intra healthy uterine pregnancy, while both FS and activin A/FS ratio had poor ability to differentiate missed miscarriage and intrauterine pregnancy.
Conclusion: Activin A can be used with high accuracy as a biomarker for EP and missed miscarriage, FS alone, and activin A/FS ratio is a possible biomarker, but it offers lower accuracy compared to activin A alone.
2. Al-hakeim HA, Jebur IM, Alkhafaji RS. Serum anti-zona pellucida antibodies is correlaterd with estradiol level in women with in vitro fertilization failure. Int J Pharm Pharm Sci 2016;8:41-4.
3. Reis FM, Luisi S, Abrão MS, Rocha AL, Viganò P, Rezende CP, et al. Diagnostic value of serum activin a and follistatin levels in women with peritoneal, ovarian and deep infiltrating endometriosis. Hum Reprod 2012;27:1445-50.
4. Koninger A, Schmidt B, Damaske D, Birdir C, Enekwe A, Kimmig R, et al. Follistatin during pregnancy and its potential role as an ovarian suppressing agent. Eur J Obstet Gynecol Reprod Biol 2017;212:150-400.
5. Hedger MP, Winnall WR, Phillips DJ, de Kretser DM. The regulation and functions of activin and follistatin in inflammation and immunity. Vitam Horm 2011;85:255-97.
6. Ekechi CI. Spontaneous miscarriage. In: Edmonds KD, editor. Dewhurst’s Textbook of Obstetrics and Gynaecology. 9th ed. USA: John Wiley and Sons Ltd.; 2018. p. 559-67.
7. Alomar MJ. Evaluation of caffeine consumption and effect during pregnancy among women in UAE. Int J Pharm Pharm Sci 2016;8:101-3.
8. Kirk E, Bottomley C, Bourne T. Diagnosing ectopic pregnancy and current concepts in the management of pregnancy of unknown location. Hum Reprod Update 2013;20:250-61.
9. Ekechi CI, Stalder CM. Spontaneous miscarriage. In: Edmonds DK, editor. Dewhurst’s Textbook of Obstetrics and Gynaecology. 19th ed. Chichester, UK: Wiley-Blackwell; 2019. p. 559-67.
10. NICE Clinical Guidelines 126. Ectopic Pregnancy and Miscarriage, Diagnosis and Initial Management. NICE Clinical Guidelines; 2019.
11. Bearfield C, Jauniaux E, Groome N, Sargent I, Muttukrishna S. The secretion and effect of inhibin A, activin A and follistatin on first-trimester trophoblasts in vitro. Eur J Endocrinol 2005;152:909-16.
12. Muttukrishna S, Jauniaux E, Pahal G, Groome N, Rodeck C, editors. In vivo Distribution of Inhibin A, Activin A and Follistatin in Early Pregnancy. European: Congress in Obstetrics and Gynaecology Ceska Gynekol; 2002.
13. Rausch ME, Sammel MD, Takacs P, Chung K, Shaunik A, Barnhart KT. Development of a multiple marker test for ectopic pregnancy. Obstet Gynecol 2011;117:573-82.
14. Warrick J, Gronowski A, Moffett C, Zhao Q, Bishop E, Woodworth A.Serum activin A does not predict ectopic pregnancy as a single measurement test, alone or as part of a multi-marker panel including progesterone and hCG. Clin Chim Acta 2012;413:707-11.
15. Florio P, Severi FM, Bocchi C, Luisi S, Mazzini M, Danero S, et al. Single serum activin a testing to predict ectopic pregnancy. J Clin Endocrinol Metab 2007;92:1748-53.
16. Johns J, Muttukrishna S, Lygnos M, Groome N, Jauniaux E. Maternal serum hormone concentrations for prediction of adverse outcome in threatened miscarriage. Reprod Biomed Online 2007;15:413-21.
17. Daponte A, Deligeoroglou E, Garas A, Pournaras S, Hadjichristodoulou C, Messinis IE. Activin A and follistatin as biomarkers for ectopic pregnancy and missed abortion. Dis Markers 2013;35:497-503.
18. Muttukrishna S, Jauniaux E, Greenwold N, McGarrigle H, Jivraj S, Carter S, et al. Circulating levels of inhibin A, activin A and follistatin in missed and recurrent miscarriages. Hum Reprod 2002;17:3072-8.
19. Kirk E, Papageorghiou AT, Van Calster B, Condous G, Cowans N, Van Huffel S, et al. The use of serum inhibin A and activin A levels in predicting the outcome of “pregnancies of unknown location”. Hum Reprod 2009;24:2451-6.
20. Únior JE, Oliveira LG, Silva MO, Júnior EA, Camano L. Serum activin A levels and tubal ectopic pregnancy. Iran J Reprod Med 2014;12:227.
21. Luisi S, Florio P, D’Antona D, Severi F, Sanseverino F, Danero S, et al. Maternal serum inhibin A levels are a marker of a viable trophoblast in incomplete and complete miscarriage. Eur J Endocrinol 2003;148:233-6.
22. Prakash A, Laird S, Tuckerman E, Li TC, Ledger WL. Inhibin A and activin A may be used to predict pregnancy outcome in women with recurrent miscarriage. Fertil Steril 2005;83:1758-63.
23. Florio P, Reis FM, Battista R, Luisi S, Moncini I, Bocchi C, et al. Serum activin A levels are lower in tubal than intrauterine spontaneously conceived pregnancies. Gynecol Endocrinol 2011;27:391-5.
24. Kirk E, Condous G, Haider Z, Lu C, Van Huffel S, Timmerman D, et al. The practical application of a mathematical model to predict the outcome of pregnancies of unknown location. Ultrasound Obstet Gynecol 2006;27:311-5.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.